These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 30327601)
1. Risk-Return Analysis of the Biopharmaceutical Industry as Compared to Other Industries. Popa C; Holvoet K; Van Montfort T; Groeneveld F; Simoens S Front Pharmacol; 2018; 9():1108. PubMed ID: 30327601 [No Abstract] [Full Text] [Related]
2. Profitability and risk-return comparison across health care industries, evidence from publicly traded companies 2010-2019. Bai G; Rajgopal S; Srivastava A; Zhao R PLoS One; 2022; 17(11):e0275245. PubMed ID: 36383519 [TBL] [Abstract][Full Text] [Related]
4. Hospital profitability and capital structure: a comparative analysis. Valvona J; Sloan FA Health Serv Res; 1988 Aug; 23(3):343-57. PubMed ID: 3403274 [TBL] [Abstract][Full Text] [Related]
5. Industry return lead-lag relationships between the US and other major countries. Monteiro A; Silva N; Sebastião H Financ Innov; 2023; 9(1):40. PubMed ID: 36687785 [TBL] [Abstract][Full Text] [Related]
6. The Market of Biopharmaceutical Medicines: A Snapshot of a Diverse Industrial Landscape. Moorkens E; Meuwissen N; Huys I; Declerck P; Vulto AG; Simoens S Front Pharmacol; 2017; 8():314. PubMed ID: 28642701 [No Abstract] [Full Text] [Related]
7. What stock market returns to expect for the future? Diamond PA Soc Secur Bull; 2000; 63(2):38-52. PubMed ID: 11131980 [TBL] [Abstract][Full Text] [Related]
8. Profitability of Large Pharmaceutical Companies Compared With Other Large Public Companies. Ledley FD; McCoy SS; Vaughan G; Cleary EG JAMA; 2020 Mar; 323(9):834-843. PubMed ID: 32125401 [TBL] [Abstract][Full Text] [Related]
9. Just how good an investment is the biopharmaceutical sector? Thakor RT; Anaya N; Zhang Y; Vilanilam C; Siah KW; Wong CH; Lo AW Nat Biotechnol; 2017 Dec; 35(12):1149-1157. PubMed ID: 29220034 [TBL] [Abstract][Full Text] [Related]
10. Accounting- versus economic-based rates of return: implications for profitability measures in the pharmaceutical industry. Skrepnek GH Clin Ther; 2004 Jan; 26(1):155-74. PubMed ID: 14996527 [TBL] [Abstract][Full Text] [Related]
11. The impact and role of COVID-19 uncertainty: A global industry analysis. Szczygielski JJ; Charteris A; Bwanya PR; Brzeszczyński J Int Rev Financ Anal; 2022 Mar; 80():101837. PubMed ID: 36536787 [TBL] [Abstract][Full Text] [Related]
12. Wise Investment? Modeling Industry Profitability and Risk of Targeted Chemotherapy for Incurable Solid Cancers. Conter HJ; Chu QSC J Oncol Pract; 2012 Mar; 8(2):69. PubMed ID: 29447097 [TBL] [Abstract][Full Text] [Related]
13. Hurdles in tissue engineering/regenerative medicine product commercialization: a pilot survey of governmental funding agencies and the financial industry. Bertram TA; Tentoff E; Johnson PC; Tawil B; Van Dyke M; Hellman KB Tissue Eng Part A; 2012 Nov; 18(21-22):2187-94. PubMed ID: 22838399 [TBL] [Abstract][Full Text] [Related]
14. One lab, two firms, many possibilities: On R&D outsourcing in the biopharmaceutical industry. Billette de Villemeur E; Versaevel B J Health Econ; 2019 May; 65():260-283. PubMed ID: 31158785 [TBL] [Abstract][Full Text] [Related]
16. Current situation and future development of the biopharmaceutical industry in China: A mixed-method study. Yang R; Kabba JA; Yao X; Yang C; Chang J; Ji W; Jiang M; Zhao M; Wen J; Fang Y Front Pharmacol; 2022; 13():911165. PubMed ID: 36071832 [No Abstract] [Full Text] [Related]
17. Profitability of Ichimoku-Based Trading Rule in Vietnam Stock Market in the Context of the COVID-19 Outbreak. Che-Ngoc H; Do-Thi N; Nguyen-Trang T Comput Econ; 2022 Oct; ():1-19. PubMed ID: 36254141 [TBL] [Abstract][Full Text] [Related]
18. 'Financial fallout' in the US biopharmaceutical industry: Maximizing shareholder value, regulatory capture, and the consequences for patients. Whitacre R Soc Sci Med; 2024 Mar; 344():116598. PubMed ID: 38382235 [TBL] [Abstract][Full Text] [Related]
19. Economic return of clinical trials performed under the pediatric exclusivity program. Li JS; Eisenstein EL; Grabowski HG; Reid ED; Mangum B; Schulman KA; Goldsmith JV; Murphy MD; Califf RM; Benjamin DK JAMA; 2007 Feb; 297(5):480-8. PubMed ID: 17284698 [TBL] [Abstract][Full Text] [Related]
20. Franchising structure changes and shareholder value: Evidence from store buybacks and refranchising. Sadovnikova A; Kacker M; Mishra S J Acad Mark Sci; 2023; 51(5):1098-1117. PubMed ID: 37600157 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]